We evaluated the efficacy of pre-cryosurgery and post-cryosurgery circulating tumour cells (CTCs) as biomarkers for unresectable hepatocellular carcinoma (HCC). Real-time qPCR was used to detect potential biomarker genes in CTCs, and magnetic-activated cell sorting (MACS) and fluorescence-activated cell sorting (FACS) was performed on 47 patients with hepatocellular cancer who underwent cryosurgery. CTCs in the 47 patients were assessed 1 day before cryosurgery, and 7 and 30 days after cryosurgery. The number of CTCs was 17.70±5.725, 14.64±6.761 and 10.28±5.598, respectively, and this decreased significantly over time (P<0.01). ΔCt values for MAGE-3, survivin and carcinoembryonic antigen (CEA) were elevated significantly compared with those obtained before cryosurgery; 2 -ΔΔCt values were <1 before cryosurgery, and were 0.63±1.56, 0.21±0.22 and 0.22±0.34 for MAGE-3, survivin and CEA, respectively, at 7 days after treatment. At 30 days after treatment, 2 -ΔΔCt values for MAGE-3, survivin and CEA were 0.24±0.82, 0.03±0.07 and 0.02±0.08, indicating that gene expression in CTCs significantly decreased over time (P<0.01). CTCs were useful biomarkers for evaluating the efficacy of cryosurgery on unresectable HCC.
Introduction
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths worldwide. Approximately 70-80% of HCC patients are diagnosed at an advanced stage, 80% of whom have underlying cirrhosis and only 20-30% of these were able to undergo surgical resection (1) . Patients presenting with advanced or unresectable disease have a very poor prognosis, with only 12% surviving for 5-years (2) . An inability to diagnose during the early stages and insufficient therapeutic intervention results in most HCC patients progressing to metastasis, and the median survival is only a few months (3) . Local ablation therapies are now deployed to treat advanced cases, including percutaneous ethanol injection, radiofrequency ablation (RFA), cryoablation, laser treatment, high-intensity focused ultrasound and microwave treatment (4) . Argon-helium cryotherapy is also an effective local ablation therapy that has been used to treat HCC (5) . Compared with RFA and other thermal ablation techniques, cryoablation can inflict greater damage on tumour tissues and result in more clearly discernible treatment areas, and can suppress ectopic tumours (6) .
Recurrence following treatment in advanced HCC patients cannot always be prevented, and while the treatments listed above have decreased mortality, drug resistance and tumour recurrence are common and remain to be addressed (7) . The most important factor contributing to poor prognosis is the inability to diagnose the disease early, and identification of sensitive, robust circulating biomarkers is critical. Circulating tumour cells (CTCs) are cancer cells that are shed from either the primary tumour or its metastases and that circulate in the peripheral blood. While metastases are directly responsible for the majority of cancer deaths, CTCs may constitute seeds for metastases and may indicate the spread of the disease (8, 9) . CTCs are increasingly evaluated in liquid biopsies, and their analysis holds great promise for identification of patients at high-risk of relapse, for determining specific adjuvant therapies for individual patients, and for monitoring responses (10) (11) (12) . Counting the number of CTCs proved to be an independent prognostic biomarker in small cell and non-small cell lung cancer patients (13, 14) , and in other epithelial cell-derived tumours such as breast (15, 16) , colorectal (17) , and prostate cancer (18) . CTCs are often present in the blood of patients suffering metastasis, and detection in peripheral blood is highly correlated with early tumour metastases (19) . CTCs can also provide information on tumour biological activity and can facilitate the real-time prediction of prognosis in patients suffering distant metastases (17, 18, 20) . The purpose of the present study was to use immune magnetic bead flow cytometry and real-time qPCR to measure the number of CTCs in the peripheral blood of HCC patients before and after cryosurgery and to correlate with disease prognosis.
Materials and methods

Patients.
Patients with hepatocellular cancer were recruited from the Fuda Cancer Hospital of Jinan university between June 2014 and June 2015, and all accepted cryoablation therapy. inclusion and exclusion criteria were as follows: inclusion criteria: examined by imaging and clinical TNM stage iii or iV; diagnosed by pathological examination as malignant hepatocellular cancer; accepted cryosurgery in our hospital to target local tumours, metastasis and tumour recurrence in situ; voluntary consent was obtained; post-treatment survival estimated at >3 months; age >18 and <85; karnofsky performance status (kPS) score >60 points; routine blood, liver and kidney function.
Exclusion criteria: local and/or systemic chemotherapy ongoing, or finished no more than 15 days before experiments; blood coagulation disorders or severe anaemia; merging into other primary tumours; concurrent venereal disease, leprosy, AiDS or HiV infection, hepatitis, tuberculosis, blood parasites or other infectious diseases.
in total, 47 patients with HCC met the above criteria (Table Ι) and provided written consent. The present study was approved by the Ethics Committee of Fuda Cancer Hospital. Peripheral blood (17 ml) was collected at 3 time points using ACD vacuum tubes (becton-Dickinson and Co., Franklin Lakes, NJ, uSA) at 1 day before cryoablation, and at 7 and 30 days after the operation.
Percutaneous cryoablation.
Comprehensive cryoablation was performed on all 47 patients. Percutaneous cryoablation was performed under double-row helical computed tomography (SOMATOM Emotion Duo; Siemens, Munich, Germany) or color ultrasound (ALOkA-SSD-5500A; Aloka, Tokyo, Japan) guidance. All cryosurgery was performed by Lizhi Niu and assistants (Haibo Li and Feng Mu). Each procedure comprised 1-3 freeze/thaw cycles accomplished using an argon gas-based cryosurgical unit (Endocare Corp., irvine, CA, uSA) (21, 22) . Depending on the location of the metastasis, probes were inserted percutaneously under ultrasound or CT guidance; 2 or 5 mm probes or rarely, 10 mm probes (Cryo-42; Endocare Corp.) were used according to the size of the tumour. Two or more probes were simultaneously used for large lesions. individual tumours were frozen sequentially on a tumour by tumour basis. The duration of freezing depended on the formation of an ̔ice ball̓ visible on ultrasonography as a hypoechogenic area >1 cm larger than the diameter of the lesion. Thawing was achieved by input of helium for a period of time equal to the freezing time before the next freezing process was begun.
Cell culture. HepG2 carcinoma cells obtained from Cell Resource Center (institute of basic Medical Sciences, Chinese Academy of Medical Sciences/Peking union Medical College, beijing, China) were maintained in Dulbecco's modified Eagle's medium containing 10% fetal calf serum at 37˚C in a humidified atmosphere containing 5% CO 2 .
Preparation of blood samples. Samples were stored at room temperature and processed within 6 h after collection. Approximately 20 ml blood was drawn via vein puncture from each of the 47 HCC patients and from 10 healthy volunteers. blood from healthy volunteers was used to plot a standard curve for low cytometric experiments. To avoid contamination with skin cells, 5 ml blood was discarded before experimental samples were taken as previously described. Briefly, mononucleocytes were separated from other blood components using human peripheral blood lymphocyte separation liquid (Tianjin Haoyang biological Manufacture Co., Ltd., Tianjin, China) and centrifugation at 1,800 x g for 20 min at 4˚C. Interface cells were removed and washed, and RbCs were removed using bD Pharm Lyse™ (becton-Dickinson, San Jose, CA, uSA). Following further washes, mononuclear cells were counted and samples were divided into two for RT-PCR and multiparameter flow cytometric experiments (each sample contained at least 2-3x10 6 cells. Cell pellets were resuspended in phosphate-buffered saline (PbS) (Life Technologies, Shanghai, China) for multiparameter flow cytometry, then in TRizol reagent following counting using a TC10™ automatic cell count meter (bio-Rad, Hercules, CA, uSA). Viable cells were stained using trypan blue solution (Life Technologies, Carlsbad, CA, USA) and stored at -70˚C until needed for RNA extraction. (10 µl) and specific for epithelial cells (CD326/Ep-CAM) labelled with allophycocyan (APC) (10 µl) were added/7.5 ml whole blood. Cell pellets were resuspended in 500 µl PBS and counted by flow cytometry using a bD FACSCanto™ ii apparatus (becton-Dickinson). Cells that were CD45-negative, CK-and CD326-positive were defined as CTCs.
Real-time qPCR. Primers for GAPDH and tumour markers survivin, MAGE-3 and CEA (Table ΙΙ) have been reported previously (23) (24) (25) (26) , and were synthesized by the Shanghai Yingweijieji Corporation. RNA was extracted from frozen samples using 1 ml TRizol (Life Technologies). After thawing, 0.2 ml chloroform (Guangzhou Chemical Reagent Factory, Guangzhou, China) was added and samples were centrifuged at 13,500 x g for 15 min at 4˚C. Supernatants containing intact RNA were placed into fresh tubes, and RNA was precipitated with 500 µl isopropyl alcohol washed with 75% ethanol (both from Tianjin Fuyu Fine Chemical Co., Ltd., Tianjin, China), and dissolved in 50 µl RNase-free water. using a Thermo Scientific Multiskan Go (Thermo Fisher, Shanghai, China), RNA concentration and purity were measured, and RNA was diluted to the required concentration. Amplifications were performed in 8-tube strips and subjected to one-step qPCR detection using SYbR-Green i following an initial reverse transcription step. Reactions (20 µl) contained 10 µl of 2X One-Step SYbR RT-PCR buffer 4, 0. ). After adjusting GADPH gene expression to equal 1, 2 -ΔΔCt gave the level of gene expression relative to that before cryotherapy.
Data were analyzed using SPSS version 20.0 (ibM, Armonk, NY, uSA) and expressed as means ± SD. Random analysis of variance was performed and P<0.05 was considered statistically significant, whereas P<0.01 was considered statistically significant for expression differences. GraphPad Prism version 6.0 (GraphPad Software, inc., San Diego, CA, uSA) was used to plot all graphs.
Results
Flow cytometry. A standard curve was plotted using data from HepG2 cells from healthy volunteers, and serial dilution (0.0001, 0.001, 0.005 and 0.05%) of human HepG2 tumour cells in volunteers blood established a lower detection limit of 0.001%, equivalent to one cell/100,000 white blood cells (Fig. 1A-D) . below this level, background noise makes the signal unreliable. Recovery and linearity were highly reproducible across 3 separate experiments (Fig. 1E) , and the number of tumour events recovered could be positively correlated with the number of tumour events expected based on serial dilution (R 2 =0.9998). Peripheral blood CTCs from all the 47 patients was tested at 1 day before HCC cryosurgery, and at 7 and 30 days after surgery (Fig. 2) . The number of CTCs at 1 day before surgery was set as the baseline and was 17.70±5.725. The number of CTCs 7 and 30 days after surgery was 14.64±6.761 and 10.28±5.598, respectively. Random analysis of variance was performed using SPSS version 20.0, which demonstrated that the number of CTCs in peripheral blood decreased significantly after cryosurgery (P<0.01; Table ΙΙΙ) . ΔCt (Fig. 4) . 2 -ΔΔCt values correspond to the fold-change in relative gene expression, and since all postoperative values were <1, cryosurgery clearly decreased CTC markers, and the decrease was larger over time. 12  9  11  P18  14  16  13  P19  21  17  22  P20  13  15  8  P21  14  11  7  P22  26  18  21  P23  16  14  12  P24  25  23  27  P25  21  14  17  P26  21  11  9  P27  27  12  10  P28  16  8  11  P29  13  11  14  P30  14  7  5  P31  18  15  13  P32  26  16  17  P33  24  18  10  P34  17  19  8  P35  25  13  10  P36  14  10  9  P37  13  19  6  P38  16  10  12  P39  19  11  8  P40  11  7  2  P41  18  21  14  P42  31  42  19  P43  19  24  14  P44  3  2  0  P45  26  20  5  P46  11  23  2  P47  19  24  7 CTCs, circulating tumour cells. 
Real-time qPCR Changes in
Discussion
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths worldwide. At present, tumour resection and liver transplantation are the most effective treatments (28, 29) , but unresectable lesions are treated using ablation therapies such as percutaneous ethanol injection, radiofrequency ablation (RFA), cryoablation, laser treatment, high-intensity focused ultrasound and microwave treatment (4). Argon-helium cryotherapy has also been tested on HCC (5) and was shown to cause greater damage to tumour tissues (6) . Additionally, treatment areas are more easily discernible, and the therapy can successfully suppress ectopic tumours. Although these treatments have decreased HCC mortality, recurrence in advanced HCC patients is common and difficult to prevent. Nowadays, serum AFP, a secretory protein, is widely used for diagnosing HCC patients and monitoring disease progression, but it has a sensitivity ranging from 39-97% and a specificity ranging from 76-95%, even when used to screen high-risk populations (30) (31) (32) . A more reliable biomarker is ideally needed in the clinic, a circulating tumour cells (CTCs) may provide a more sensitive and robust circulating biomarker. CTCs are cancer cells that have been shed from either the primary tumour or its metastases and that circulate in the peripheral blood. While metastases are directly responsible for the majority of cancer deaths, CTCs may constitute seeds for metastases and may indicate the spread of disease (8, 9) . CTCs in liquid biopsies can provide information on the risk of relapse, can help to determine which specific adjuvant therapies may be appropriate, and can be used to monitor responses to treatment (10) (11) (12) . For advanced HCC patients with or without other organ metastasis, conventional treatments generally have little effect. Argon-helium knife cryoablation therapy is a novel local treatment that is minimally invasive, thus intraoperative complications such as bleeding and infection are less prevalent than in conventional surgery. However, as with conventional surgery, the risk of postoperative blood or lymphatic metastasis is high, and tumour recurrence, metastasis and ultimately death may result. improving the survival and quality of life for patients with locally advanced disease remains a priority, and new methods for diagnosis and establishing prognosis are much needed.
Counting the number of CTCs may aid cancer diagnosis and help predict the likelihood of recurrence, and can also be used to monitor the effectiveness of postoperative radiotherapy and chemotherapy (33) . Additionally, dynamic detection of peripheral blood CTCs is likely to become a reliable prognostic indicator for locally advanced hepatocellular cancer patients, and may help to quickly identify those with a high-risk of recurrence, thus improving survival rate and quality of life. The isolation and identification of CTCs have developed rapidly in recent years, and fluorescence-activated cell sorting (FACS) combined with magnetic-activated cell sorting (MACS) quantitatively analyzes and sort single cells and biological particles at the functional level. This technique can analyze thousands of cells at high speed, and can detect multiple parameters of a single cell simultaneously, which is a big advantage over conventional fluorescent approaches in terms of speed and precision. Flow cytometric detection of peripheral blood CTCs is dependent on the expression of tumour-specific markers such as cytokeratins (Cks) on the surface of epithelial cells. Cks are proteins that consist of keratin-containing intermediate filaments that form the intracytoplasmic cytoskeleton, and their expression primarily depends on the type of epithelia, the degree of terminal differentiation and the stage of development (34) . in many cases, cytokeratin expression in tumours and peripheral blood has prognostic significance for cancer patients, and Ck8/18/19 expression has been used as a biomarker for HCC histopathology (35, 36) . in order to reduce the occurrence of false negatives, we used CD326 (EpCAM) as an additional specific marker for positive selection (37) , and used CD45 for negative selection of leukocytes (38) . Flow cytometry can then be used to detect double-positive CTCs (CD45 -, Ck + and CD326 + ). in the present study, we applied this method to detect peripheral blood CTCs in 47 patients with locally advanced HCC. After cryoablation therapy, the number of peripheral blood CTCs was markedly decreased (P<0.01), indicating potential usefulness for prognostic evaluation of cryosurgery. Although promising, at present there is no effective method for evaluating the surgical success of argon-helium knife cryoablation, and the results of the present study may provide a breakthrough in this area.
At 7 days after surgery, the number of CTCs in peripheral blood increased in 14/47 patients (29.79%) compared with preoperative numbers, but all patients exhibited a marked decrease at 30 days after surgery (Fig. 5) . This may be due to the large number of CTCs released into the blood during surgery and a delay in their removal by the immune system. The initial postoperative rise may be associated with immunity following cryoablation, since tumours release antigen that can lead to ̔high zone tolerance̓ immunosuppression (39) . This can reduce the ability of the immune system to recognise tumour cells, but immune enhancement could reverse this process to decrease CTCs by 30 days post-surgery (40) .
RT-qPCR is a commonly used and effective method for measuring gene expression and detecting CTCs. This method is highly sensitive, quantitative, rapid, non-polluting and facilitates monitoring in real-time. RT-PCR also overcomes the high rate of false positives that can be a problem for traditional PCR-based methods. in the present study, we used an RT-qPCR method to measure expression of the reference gene GADPH, along with the metastasis-associated markers MAGE-3, survivin and CEA in CTCs from 47 locally advanced HCC patients before and after cryotherapy. The results showed that CTCs in peripheral blood decreased following cryosurgery (P<0.01), indicating a lower risk of tumour recurrence and metastasis following this type of therapeutic intervention. Patients expressing high levels of these CTC markers are likely to have poor prognosis with increased risk of recurrence and/or metastasis. Our method is therefore suitable for evaluation of cryotherapy.
Numerous tumour treatments involve local surgical excision of legions, and while initial results are often promising, recurrence and/or metastasis can occur, and eradication of all cancerous cells can be very difficult to achieve. Such as all existing cancer treatments, cryosurgery is not perfect, and changes in the immune system following surgery can influence the therapeutic outcome. Our results indicate that detection of CTCs in liquid biopsy experiments could help to determine whether cryosurgery is likely to be successful. in the future, detection of CTCs could conceivably replace radioscopy for early detection of cancers and/or re-examination following surgery and postoperative radiotherapy and chemotherapy.
